Trina Solar made a spectacular appearance at SNEC 2025, showcasing multiple cutting-edge technologies and zero-carbon future+ ...

From a market perspective, Vertex's stock trades at a high P/E ratio of 29.08, which, when adjusted for the last twelve months as of Q4 2023, stands at a slightly lower figure of 26.23.

On Tuesday, BofA Securities analysts reaffirmed a Buy rating and maintained a $567.00 price target on Vertex stock (NASDAQ: VRTX), a prominent player in the Biotechnology industry with a market ...

Vanguard plans new, low-fee ex-China emerging markets fund New ETF would bring roster of ex-China products to 13 Appetite for ex-China emerging markets waning amid Chinese stock rebound June 2 ...

"It worked amazingly well," Julian Field told the crowd at Vertex Wednesday. "I couldn't unsee what I'd seen." William G. Cobb of the General Motors Corp. demonstrated the world’s first solar ...

Vanguard Dividend Appreciation ETF (NYSEMKT: VIG) is an interesting exchange-traded fund (ETF). It has the word dividend in the name, but it really doesn't have a high yield at around 1.8%.

On Friday, BMO Capital Markets confirmed its positive stance on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), maintaining both the Outperform rating and the $557.00 price target for the ...

Continue » This stock is Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF ...

The Vanguard S&P 500 ETF (NYSEMKT: VOO) became the world's largest exchange-traded fund (ETF) earlier this year when it surpassed the SPDR S&P 500 ETF Trust. Both funds track the performance of ...

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...